Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Minjie GaoJumei Shi

Abstract

The efficacy and safety of thalidomide as an initial treatment in myeloma patients who were unsuitable for autologous stem cell transplantation (ASCT), as induction treatment prior to ASCT, or as a maintenance treatment was unclear. The purpose of this study was to assess the benefits and risks of thalidomide for previously untreated myeloma patients. MEDLINE, EMBASE, and Cochrane Library were searched for randomized controlled trials (RCTs) of thalidomide used in either induction or maintenance therapy for previously untreated myeloma patients. Twenty-two RCTs enrolling 9098 patients were identified, including 15 RCTs of induction thalidomide, 6 RCTs of maintenance thalidomide, and 1 RCT of induction and maintenance thalidomide. Induction thalidomide improved overall response rate (ORR) (risk ratio (RR) 1.54, 95 % confidence interval (CI) 1.30-1.83), complete response rate (CRR) (RR 3.03, 95 % CI 1.91-4.80), progression-free survival (PFS) (hazard ratio (HR) 0.65, 95 % CI 0.56-0.76), and overall survival (OS) (HR 0.78, 95 % CI 0.67-0.91) in patients who were not allowed to receive ASCT. Induction thalidomide improved pre-ASCT ORR (RR 1.20, 95 % CI 1.11-1.30), pre-ASCT and post-ASCT CRR (RR 1.47, 95 % CI 1.12-1.93 and RR 1.23, ...Continue Reading

References

Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Dec 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vincent RajkumarUNKNOWN Eastern Cooperative Oncology Group
Jul 29, 2006·Blood·Michel AttalUNKNOWN Inter-Groupe Francophone du Myélome (IFM)
Aug 19, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K ZervasUNKNOWN Greek Myeloma Study Group
Mar 26, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vincent RajkumarJoan Bladé
Apr 3, 2008·Cancer Treatment Reviews·Lisa K HicksUNKNOWN Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care
Mar 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew SpencerNola Kennedy
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cyrille HulinPhilippe Moreau
May 8, 2010·Blood·Anders WaageUNKNOWN Nordic Myeloma Study Group
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre WijermansUNKNOWN Dutch-Belgium Cooperative Group HOVON
Oct 25, 2011·Blood·Gareth J MorganUNKNOWN National Cancer Research Institute Haematological Oncology Clinical Studies Group
Jun 26, 2012·American Journal of Hematology·Angelo MaiolinoUNKNOWN Brazilian Multiple Myeloma Study Group (BMMSG/GEMOH)
Sep 12, 2014·Computational and Structural Biotechnology Journal·Ivan Spicka

❮ Previous
Next ❯

Citations

Dec 3, 2016·Journal of Psychopharmacology·Jeffrey A Lieberman, Daniel Shalev
Jan 31, 2019·Expert Review of Hematology·Iuliana Vaxman, Morie Gertz
Sep 21, 2017·Oncology Letters·Clemens B TempferGünther A Rezniczek

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Cancer Treatment Reviews
Lisa K HicksHematology Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care
Hispalis médica; revista sevillana de medicina y cirugia
A GONZALEZ MENESES
Clinical Journal of Oncology Nursing
A R Waldman
The Medical Letter on Drugs and Therapeutics
© 2022 Meta ULC. All rights reserved